Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benefit: Gefitinib in EGFR-mutated Lung Adenocarcinoma
NCT02282267Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gefitinib in lung adenocarcinoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02282267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282267.